Switch theme
Sign up to access all valuation multiples
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.
2007
n/a
LTM Revenue $3.4M
LTM EBITDA -$8.0M
$59.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Recce Pharmaceuticals has a last 12-month revenue (LTM) of $3.4M and a last 12-month EBITDA of -$8.0M.
In the most recent fiscal year, Recce Pharmaceuticals achieved revenue of n/a and an EBITDA of -$10.6M.
Recce Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Recce Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$8.0M | XXX | -$10.6M | XXX | XXX | XXX |
| EBITDA Margin | -237% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$8.2M | XXX | -$14.2M | XXX | XXX | XXX |
| EBIT Margin | -244% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$8.5M | XXX | -$11.3M | XXX | XXX | XXX |
| Net Margin | -253% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Recce Pharmaceuticals's stock price is AUD 0 (or $0).
Recce Pharmaceuticals has current market cap of AUD 94.3M (or $60.6M), and EV of AUD 93.2M (or $59.8M).
See Recce Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $59.8M | $60.6M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Recce Pharmaceuticals has market cap of $60.6M and EV of $59.8M.
Recce Pharmaceuticals's trades at n/a EV/Revenue multiple, and -6.5x EV/EBITDA.
Equity research analysts estimate Recce Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Recce Pharmaceuticals has a P/E ratio of -7.1x.
See valuation multiples for Recce Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $60.6M | XXX | $60.6M | XXX | XXX | XXX |
| EV (current) | $59.8M | XXX | $59.8M | XXX | XXX | XXX |
| EV/Revenue | 17.8x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -7.5x | XXX | -6.5x | XXX | XXX | XXX |
| EV/EBIT | -7.3x | XXX | -5.4x | XXX | XXX | XXX |
| EV/Gross Profit | 17.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.1x | XXX | -6.2x | XXX | XXX | XXX |
| EV/FCF | -7.5x | XXX | -7.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRecce Pharmaceuticals's last 12 month revenue growth is -40%
Recce Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Recce Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Recce Pharmaceuticals's rule of X is -338% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Recce Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -40% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -237% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 83% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -338% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Recce Pharmaceuticals acquired XXX companies to date.
Last acquisition by Recce Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Recce Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Recce Pharmaceuticals founded? | Recce Pharmaceuticals was founded in 2007. |
| Where is Recce Pharmaceuticals headquartered? | Recce Pharmaceuticals is headquartered in Australia. |
| Is Recce Pharmaceuticals publicy listed? | Yes, Recce Pharmaceuticals is a public company listed on ASX. |
| What is the stock symbol of Recce Pharmaceuticals? | Recce Pharmaceuticals trades under RCE ticker. |
| When did Recce Pharmaceuticals go public? | Recce Pharmaceuticals went public in 2016. |
| Who are competitors of Recce Pharmaceuticals? | Similar companies to Recce Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Recce Pharmaceuticals? | Recce Pharmaceuticals's current market cap is $60.6M |
| What is the current revenue of Recce Pharmaceuticals? | Recce Pharmaceuticals's last 12 months revenue is $3.4M. |
| What is the current revenue growth of Recce Pharmaceuticals? | Recce Pharmaceuticals revenue growth (NTM/LTM) is -40%. |
| What is the current EV/Revenue multiple of Recce Pharmaceuticals? | Current revenue multiple of Recce Pharmaceuticals is 17.8x. |
| Is Recce Pharmaceuticals profitable? | Yes, Recce Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Recce Pharmaceuticals? | Recce Pharmaceuticals's last 12 months EBITDA is -$8.0M. |
| What is Recce Pharmaceuticals's EBITDA margin? | Recce Pharmaceuticals's last 12 months EBITDA margin is -237%. |
| What is the current EV/EBITDA multiple of Recce Pharmaceuticals? | Current EBITDA multiple of Recce Pharmaceuticals is -7.5x. |
| What is the current FCF of Recce Pharmaceuticals? | Recce Pharmaceuticals's last 12 months FCF is -$8.0M. |
| What is Recce Pharmaceuticals's FCF margin? | Recce Pharmaceuticals's last 12 months FCF margin is -237%. |
| What is the current EV/FCF multiple of Recce Pharmaceuticals? | Current FCF multiple of Recce Pharmaceuticals is -7.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
